-
Revue Medicale de Liege 2005Peripheral neuropathy is a very frequent consequence of diabetes mellitus. Its clinical expression is quite variable. A specific therapy is sometimes necessary. Early... (Review)
Review
Peripheral neuropathy is a very frequent consequence of diabetes mellitus. Its clinical expression is quite variable. A specific therapy is sometimes necessary. Early diagnosis of diabetic neuropathy is a cornerstone of patient's follow-up. Differential diagnosis of diabetic neuropathy is sometimes difficult from another type of neuropathy or a focal, even systemic, disease. It is mandatory to know how a diabetic neuropathy may express. Pathophysiological mechanisms involved in diabetic neuropathy are complex and interrelated. Hyperglycaemia alone, even mild or moderate, vascular disorders and dysimmune factors may be combined to induce axonal injury. Glycaemic control is the cornerstone of effective treatment for neuropathy associated with diabetes. Specific pain control and therapies of autonomic disturbances are regularly required.
Topics: Diabetes Complications; Humans; Hyperglycemia; Pain; Pain Management; Peripheral Nervous System Diseases
PubMed: 16035316
DOI: No ID Found -
Neoplasma Feb 2023Chemotherapy-induced peripheral neuropathy is one of the most frequent dose-limiting side effects, observed in patients receiving antineoplastic agents, persisting for... (Review)
Review
Chemotherapy-induced peripheral neuropathy is one of the most frequent dose-limiting side effects, observed in patients receiving antineoplastic agents, persisting for up to two years after completing treatment, greatly affecting both the course of chemotherapy and patients' quality of life. Approximately 20 to 85% of patients treated with neurotoxic chemotherapy will develop peripheral neuropathy and there is considerable variability in its severity among patients. The main symptoms are numbness, paresthesia, and burning pain in a "glove and stocking" distribution. The prevalence of chemotherapy-induced peripheral neuropathy will likely increase as cancer survival rates continue to improve. Currently, there are only a few therapeutic options available for the prevention or successful therapy because the mechanisms of chemotherapy-induced peripheral neuropathy remain unclear. A better understanding of the risk factors and underlying mechanisms of chemotherapy-induced peripheral neuropathy is needed to develop effective preventive and therapeutic strategies.
Topics: Humans; Quality of Life; Antineoplastic Agents; Peripheral Nervous System Diseases; Neoplasms; Risk Factors
PubMed: 36573482
DOI: 10.4149/neo_2022_221007N992 -
Oncology Nursing Forum May 2017Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting chemotherapy toxicity, which has a long-lasting effect and decreases quality of life. Although... (Review)
Review
PROBLEM IDENTIFICATION
Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting chemotherapy toxicity, which has a long-lasting effect and decreases quality of life. Although several tools have been developed to detect CIPN, the study quality, psychometric properties, and practicality of CIPN assessment tools have not been systematically reviewed. .
LITERATURE SEARCH
Electronic searches using keywords were conducted in Medline, PubMed, CINAHL®, and Cochrane Library for articles published from 1980-2015. Eligible studies were included if they involved patients with cancer receiving chemotherapy, provided CIPN assessment tools with psychometric properties, and were published in English. .
DATA EVALUATION
Data were extracted, and study quality was assessed. CIPN tools were evaluated in terms of psychometric properties and practicality. .
SYNTHESIS
A total of 19 studies describing 20 tools were reviewed. The quality of studies varied from strong to weak. The validity ranged from low to high, and the reliability with internal consistency ranged from 0.56-0.96. Poor inter-rater agreement was found. Not all of the tools were deemed practical. .
CONCLUSIONS
Considering the psychometric properties and practicality, two tools (Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity [FACT/GOG-Ntx] and Total Neuropathy Score [TNS]) are recommended for assessing CIPN. .
IMPLICATIONS FOR NURSING
Routine assessment of CIPN and choosing appropriate assessment tools are imperative. The FACT/GOG-Ntx and TNS are recommended for clinical use.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Diagnostic Techniques, Neurological; Female; Humans; Male; Middle Aged; Neoplasms; Peripheral Nervous System Diseases; Psychometrics; Reproducibility of Results; Surveys and Questionnaires
PubMed: 28635977
DOI: 10.1188/17.ONF.E111-E123 -
Current Opinion in Anaesthesiology Oct 2017Chemotherapy-induced peripheral neuropathy (CIPN) is a common, frequently chronic condition characterized by pain and decreased function. Given the growing number of... (Review)
Review
PURPOSE OF REVIEW
Chemotherapy-induced peripheral neuropathy (CIPN) is a common, frequently chronic condition characterized by pain and decreased function. Given the growing number of cancer survivors and an increasing recognition of opioid therapy limitations, there is a need for critical analysis of the literature in directing an informed and thoughtful approach for the management of painful CIPN.
RECENT FINDINGS
A PubMed search for 'chemotherapy-induced peripheral neuropathy AND pain' identifies 259 publications between 1 January 2016 and 31 March 2017. Based on review of this literature, we aim to present a clinically relevant update of painful CIPN. Notably, the use of duloxetine as a first-line agent in treatment of CIPN is confirmed. Moreover, clinical trials focus on nonpharmacologic strategies for managing painful CIPN.
SUMMARY
Despite the volume of recent publications, there are limited preventive or therapeutic strategies for CIPN supported by high-level evidence. Duloxetine remains the only pharmacologic agent with demonstrated benefit; its clinical use should be routinely considered. Moving forward, nonopioid analgesic therapies will likely play an increasing role in CIPN treatment, but further research is necessary to confirm their utility. Promising therapies include vitamin B12 supplementation, physical therapy, and various forms of neuromodulation.
Topics: Duloxetine Hydrochloride; Humans; Peripheral Nervous System Diseases; Vitamin B 12
PubMed: 28708674
DOI: 10.1097/ACO.0000000000000500 -
Neurologic Clinics Aug 1997This article reviews the acquired causes of polyneuropathy other than diabetic and acute-onset neuropathies. The author gives a general method to simplify the diagnosis... (Review)
Review
This article reviews the acquired causes of polyneuropathy other than diabetic and acute-onset neuropathies. The author gives a general method to simplify the diagnosis of chronic polyneuropathy. The acquired polyneuropathies are discussed under four main headings: metabolic disorders, toxic or deficiency states, infections, and immune-mediated. Recent advances in therapy are emphasized, and some illustrative case histories are provided.
Topics: Biopsy; Demyelinating Diseases; Diagnosis, Differential; Humans; Neurologic Examination; Peripheral Nerves; Peripheral Nervous System Diseases; Polyneuropathies; Prognosis
PubMed: 9227950
DOI: 10.1016/s0733-8619(05)70331-5 -
Journal of the Peripheral Nervous... Mar 2019The Peripheral Neuropathy Research Registry (PNRR) is a prospective cohort of peripheral neuropathy (PN) patients focused on idiopathic axonal peripheral neuropathy....
The Peripheral Neuropathy Research Registry (PNRR) is a prospective cohort of peripheral neuropathy (PN) patients focused on idiopathic axonal peripheral neuropathy. Patients with diabetic, human immunodeficiency virus-, and chemotherapy-induced peripheral neuropathies are enrolled as comparison groups. The PNRR is a multi-center collaboration initiated and funded by the Foundation for Peripheral Neuropathy (FPN) with the objective to recruit a well characterized cohort of patients with different phenotypes and symptoms in each diagnostic category, and to advance research through development of biomarkers and identification of previously unknown causes of PN. The overall goal of the initiative is to find disease-altering treatments and better symptom relief for patients. We present the study design, types of data collected, and characteristics of the first 1150 patients enrolled. We also discuss ongoing analyses on this dataset, including untargeted-omics methodologies.
Topics: Adult; Aged; Aged, 80 and over; Clinical Protocols; Female; Humans; Male; Middle Aged; Peripheral Nervous System Diseases; Prospective Studies; Registries; Young Adult
PubMed: 30629307
DOI: 10.1111/jns.12301 -
Biomolecules & Biomedicine May 2024Diabetes mellitus, a chronic metabolic disorder characterized by hyperglycemia, has become a global health concern with an increasing prevalence worldwide. The... (Review)
Review
Diabetes mellitus, a chronic metabolic disorder characterized by hyperglycemia, has become a global health concern with an increasing prevalence worldwide. The International Diabetes Federation (IDF) estimates that over 537 million adults currently have diabetes, and they project that this figure will likely exceed 780 million by 2045. In addition, a further 541 million adults are thought to exhibit impaired glucose tolerance/prediabetes. Among its many complications, diabetic peripheral neuropathy (DPN) affects up to 50% of sufferers, with some studies showing that its prevalence, even in prediabetes, may be as high as 77%. Read more in the PDF.
Topics: Humans; Diabetic Neuropathies; Exercise; Peripheral Nervous System Diseases; Exercise Therapy
PubMed: 38215034
DOI: 10.17305/bb.2023.10188 -
Current Opinion in Neurology Oct 1995
Review
Topics: Diabetic Neuropathies; Humans; Inflammation; Leprosy; Peripheral Nervous System Diseases
PubMed: 8542035
DOI: 10.1097/00019052-199510000-00001 -
Lancet (London, England)
Topics: Diabetic Neuropathies; Humans; Peripheral Nervous System Diseases
PubMed: 15530622
DOI: 10.1016/S0140-6736(04)17346-7 -
Lancet (London, England)
Topics: Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Peripheral Nervous System Diseases
PubMed: 15530619
DOI: 10.1016/S0140-6736(04)17345-5